We want cancer patients to focus on their own personal health journey, not worry about whether they have access to all the tools and information for the best possible outcome. New technologies for endometrial cancers that identify DNA mutations that inform targeted therapy are recognised internationally as the standard of care yet are not universally […]
The Missing Piece – gynaecological cancer Read More »
The HTA Review found there is urgent need for system reform, with patients experiencing profound negative consequences caused by delays in access to new treatments. This review was initiated as part of the last Medicines Agreement and as such was largely limited to Health Technology Assessment and the Pharmaceutical Benefits Schedule (PBS). While Pathology Technology
HTA Review into Improved Access to Medicines Read More »
Pathology Technology Australia and InGeNA Limited welcome the move to legislate a total ban on the use of genomic data by Life Insurers to discriminate against individuals. “If Australia is to maintain equitable, timely, and economically sustainable healthcare for all Australians we will need to pivot towards more predictive, preventative, and personalised methods of healthcare
Joint statement supporting the ban on genetic discrimination in life insurance Read More »
After a week in hospital with dangerously high blood pressure, Sarah’s body finally went into seizure and she was rushed into an emergency C-section, with her baby not yet full term. “If I had access to a test that could predict my risk for pre-eclampsia I could have prevented a life threatening situation for
The Missing Piece – Sarah’s pre-eclampsia story Read More »